ArticleAdvanced healthcare materials2026
Design and Synthesis of Peptide-Polyester Conjugates for Cell-Mediated Scaffold Degradation.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hybrid SES-MEW Scaffold Strategies: A Narrative Review of Multi-Scale Fiber Architectures for Soft and Hard Tissue Engineering.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Biodegradable polyesters are promising biomaterials for tissue engineering. Polycaprolactone (PCL) is particularly attractive for orthopedic applications like craniofacial bone repair but does not degrade at the same rate as new tissue formation, which may compromise functional regeneration. To address this, we incorporated a protease-cleavable peptide directly into the PCL backbone. A functional mass spectrometry approach was used to identify a fast-degrading peptide (Fast) selectively cleaved by multiple cell types. Conjugates containing Fast or its scrambled control (ScrFast) were solvent-cast with an RGDS-PCL conjugate into disks. Including Fast and ScrFast peptides did not impair cell adhesion. Cy3-labeling enabled real-time quantification of degradation in the presence of collagenase or human mesenchymal stromal cells (hMSCs). After 21 days in collagenase, Fast-PCL released 20.38 ± 2.17 nmol Cy3 (25.77% ± 3.70%) vs. 8.70 ± 0.92 nmol (11.31% ± 1.01%) for ScrFast-PCL with respective mass losses of 22.1% ± 1.2%, and 18.9 ± 3.8%, indicating enzyme-mediated degradation. Under hMSC-mediated degradation, Fast-PCL released 30.31 ± 3.18 nmol Cy3 (26.68% ± 2.17%) compared to 23.91 ± 2.13 nmol (18.97% ± 1.24%) from ScrFast-PCL, indicating sequence-dependent, cell-directed resorption. This platform integrating protease-sensitive peptides into the polymer backbone can be leveraged to couple scaffold remodeling to enhance tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.